Entities / Company
Cogent Biosciences (United States).
company in Waltham, United States
- Reports this week
- 0
- Active events
- 0
- Connections
- 31
What's happening
One to three months ago
Gone quiet
No new reports in 90+ days-
Cogent Biosciences' SUMMIT trial showed strong results for its drug, leading Jefferies to raise its price target.Some support1 report
-
Cogent Biosciences plans to submit a drug application to the FDA for bezuclastinib, which was studied using TSS.Speculative1 report
-
Cogent Biosciences filed an offering with the SEC, with Leerink partners as the joint book-running manager and Broadridge handling prospectus info.Some support3 reports
-
Steve Cohen rated Cogent Biosciences as a buy, coinciding with Citibank raising its price target on the stock.Some support1 report
-
Cogent Biosciences adhered to Nasdaq Listing Rule 5635(c)(4) and is developing therapies targeting the KIT D816V mutation.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Cogent Biosciences (United States) this week
News at the entities that move Cogent Biosciences (United States) most-
FDA StructuralFDA-approved products are subject to Controlled Substances Act rules, impacting TerrAscend's operations across Pennsylvania, Maryland, New Jersey, and Ohio.Moves Cogent Biosciences (United States)
-
Leerink partners TransactionalLeerink Partners is acting as a placement agent for First Tracks Biotherapeutics.Moves Cogent Biosciences (United States)
Connections
The 4 strongest of 31, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
SUMMIT Operational
Cogent Biosciences relies on SUMMIT trial results for reporting and operational decisions.
-
Andrew B Robbins Structural
Andrew B Robbins serves as the President and CEO of Cogent Biosciences, leading its strategic financing efforts.
-
FDA Structural
Cogent Biosciences plans to submit drug applications to the FDA for regulatory review.
-
Leerink partners Transactional
Leerink partners acted as a joint book-running manager for Cogent Biosciences.
History
Events by the month they beganJune 2026
6 events- Cogent Biosciences plans to submit an NDA to the FDA, with Andrew Robbins as President and CEO.
- Cogent Biosciences' SUMMIT trial showed strong results for its drug, leading Jefferies to raise its price target.
- Cogent Biosciences plans to submit a drug application to the FDA for bezuclastinib, which was studied using TSS.
- Cogent Biosciences filed an offering with the SEC, with Leerink partners as the joint book-running manager and Broadridge handling prospectus info.
- Steve Cohen rated Cogent Biosciences as a buy, coinciding with Citibank raising its price target on the stock.
- Cogent Biosciences adhered to Nasdaq Listing Rule 5635(c)(4) and is developing therapies targeting the KIT D816V mutation.